We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adma Biologics (ADMA - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adma Biologics is a member of our Medical group, which includes 947 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 1.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ADMA has returned 18.8% so far this year. Meanwhile, stocks in the Medical group have gained about 6.2% on average. This shows that Adma Biologics is outperforming its peers so far this year.
Artivion (AORT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 59.1%.
The consensus estimate for Artivion's current year EPS has increased 11.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Adma Biologics is a member of the Medical - Biomedical and Genetics industry, which includes 465 individual companies and currently sits at #91 in the Zacks Industry Rank. On average, stocks in this group have gained 18.8% this year, meaning that ADMA is performing better in terms of year-to-date returns.
In contrast, Artivion falls under the Medical - Instruments industry. Currently, this industry has 81 stocks and is ranked #99. Since the beginning of the year, the industry has moved +3%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adma Biologics and Artivion as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adma Biologics (ADMA - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adma Biologics is a member of our Medical group, which includes 947 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adma Biologics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADMA's full-year earnings has moved 1.6% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ADMA has returned 18.8% so far this year. Meanwhile, stocks in the Medical group have gained about 6.2% on average. This shows that Adma Biologics is outperforming its peers so far this year.
Artivion (AORT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 59.1%.
The consensus estimate for Artivion's current year EPS has increased 11.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Adma Biologics is a member of the Medical - Biomedical and Genetics industry, which includes 465 individual companies and currently sits at #91 in the Zacks Industry Rank. On average, stocks in this group have gained 18.8% this year, meaning that ADMA is performing better in terms of year-to-date returns.
In contrast, Artivion falls under the Medical - Instruments industry. Currently, this industry has 81 stocks and is ranked #99. Since the beginning of the year, the industry has moved +3%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adma Biologics and Artivion as they could maintain their solid performance.